Immunotherapies for Bladder Cancer: a New Hope

Overview

Journal Curr Opin Urol

Specialty Urology

Date 2015 Sep 16

PMID 26372038

Citations 13

Authors

Farhad Fakhrejahani

Yusuke Tomita

Agnes Maj-Hes

Jane B Trepel

Maria De Santis

Andrea B Apolo

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: We review recent data on immunotherapies for bladder cancer and discuss strategies to maximize the antitumor effect of immunotherapy in solid tumors.

Recent Findings: Anti-programmed death ligand 1 has shown promise in advanced bladder cancer. Clinical trials of immune checkpoint inhibitors as monotherapy or in combination are underway. Here we review strategies for enhancing antitumor immunity using immunomodulating agents or combination treatments that may increase tumor response.

Summary: Combining immune checkpoint inhibitors with other treatment modalities may lead to the development of new treatment strategies in advanced bladder cancer; however, identifying predictive biomarkers is essential for appropriate patient selection.

Citing Articles

Immunobiology of cancer stem cells and their immunoevasion mechanisms.

Marzban H, Pedram N, Amini P, Gholampour Y, Saranjam N, Moradi S Mol Biol Rep. 2023; 50(11):9559-9573.

PMID: 37776412 DOI: 10.1007/s11033-023-08768-9.

Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis.

Guo R, Wang L, Bai S, Kang D, Zhang W, Ding Z Sci Rep. 2023; 13(1):12801.

PMID: 37550396 PMC: 10406853. DOI: 10.1038/s41598-023-39208-0.

NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.

Lu Y, Ho C, Hong J, Kuo M, Liao Y, Jaw F Mol Oncol. 2023; 17(8):1613-1627.

PMID: 36931723 PMC: 10399716. DOI: 10.1002/1878-0261.13422.

MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.

Zhu L, Liu X, Zhang W, Hu H, Wang Q, Xu K BMC Cancer. 2022; 22(1):556.

PMID: 35581573 PMC: 9112551. DOI: 10.1186/s12885-022-09606-0.

Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective.

Donini C, Rotolo R, Proment A, Aglietta M, Sangiolo D, Leuci V Cells. 2021; 10(3).

PMID: 33806296 PMC: 8001974. DOI: 10.3390/cells10030543.

References

Xylinas E, Robinson B, Kluth L, Volkmer B, Hautmann R, Kufer R . Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2013; 40(1):121-7. DOI: 10.1016/j.ejso.2013.08.023. View

Sugamura K, Ishii N, Weinberg A . Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4(6):420-31. DOI: 10.1038/nri1371. View

Auchincloss H, Turka L . CTLA-4: not all costimulation is stimulatory. J Immunol. 2011; 187(7):3457-8. PMC: 3178888. DOI: 10.4049/jimmunol.1102316. View

Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Ling V, Wu P, Spaulding V, Kieleczawa J, Luxenberg D, Carreno B . Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics. 2003; 82(3):365-77. DOI: 10.1016/s0888-7543(03)00126-5. View

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

Rozali E, Hato S, Robinson B, Lake R, Lesterhuis W . Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012; 2012:656340. PMC: 3350956. DOI: 10.1155/2012/656340. View

10.

Prise K, OSullivan J . Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009; 9(5):351-60. PMC: 2855954. DOI: 10.1038/nrc2603. View

11.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

12.

Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G . Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013; 2(6):e24612. PMC: 3716755. DOI: 10.4161/onci.24612. View

13.

Sabel M, Yamada M, Kawaguchi Y, Chen F, Takita H, Bankert R . CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother. 2000; 49(2):101-8. PMC: 11036983. DOI: 10.1007/s002620050608. View

14.

Li M, Flavell R . TGF-beta: a master of all T cell trades. Cell. 2008; 134(3):392-404. PMC: 3677783. DOI: 10.1016/j.cell.2008.07.025. View

15.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

16.

Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. DOI: 10.1200/JCO.2011.38.4032. View

17.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

18.

Li D, Sorensen L, Brooke B, Urness L, Davis E, Taylor D . Defective angiogenesis in mice lacking endoglin. Science. 1999; 284(5419):1534-7. DOI: 10.1126/science.284.5419.1534. View

19.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

20.

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View